RxDoctor Payments Data

Ronald Reichman

Rheumatology · Culver City, CANPI 1487625562

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (49.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Gilead at 27.2% of the total. Reporting peaked in 2019 at $7,939 and has fallen 89.3% since, to $850 in 2025.

$19,655in general payments, 2019–2025

Across 138 payments — averaging $142.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$5K
  • Johnson & Johnson$2K
  • UCB, Inc.$2K
  • AbbVie$2K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • plus $6K from 14 others

What the payments were for

  • Consulting fees$8,19542%
  • Speaking & faculty fees$7234%
  • Travel & lodging$1,0285%
  • Food & beverage$9,68949%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,655 in reported general payments places this provider in the 80th percentile of 808 rheumatology providers in California.

See all rheumatology providers in California →

Other rheumatology in Culver City

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →